Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 3/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1454765 | 0.90 | EGFR (0.56) | KDRMEN1KMT2AEGFRKCNK3 | |
| SCHEMBL810220 | 0.87 | AURKB (0.56) | KDRMEN1KMT2AEGFRKCNK3 | |
| SCHEMBL1455942 | 0.87 | EGFR (0.71) | KDREGFRALDH1A1BRAFAURKA | |
| SCHEMBL810676 | 0.85 | ABCG2 (0.59) | KDRMEN1KMT2AEGFRKCNK3 | |
| SCHEMBL811530 | 0.84 | EGFR (0.65) | KDRMEN1KMT2AEGFRALDH1A1 | |
| SCHEMBL809840 | 0.84 | EGFR (0.71) | MEN1KMT2AEGFRALDH1A1MAPK14 | |
| SCHEMBL810297 | 0.83 | EGFR (0.55) | KDRMEN1KMT2AEGFRKCNK3 | |
| SCHEMBL1455842 | 0.81 | AURKB (0.58) | KMT2AEGFRKCNK3KCNK9ALDH1A1 | |
| SCHEMBL810512 | 0.79 | EGFR (0.61) | MEN1KMT2AEGFRALDH1A1AURKA | |
| SCHEMBL810663 | 0.76 | KCNK3 (0.60) | KDRMEN1KMT2AEGFRKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KDR 3293/4885MEN1 4571/4885KMT2A 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.